Commodore Capital LP
Q3 2026 13F-HR Holdings
Net value change ($000)
-388,323
(-23.1%)
New positions
11
Sold out positions
7
Turnover %
35.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| DAMORA THERAPEUTICS INC | 41,262 | NEW |
| SRZN | 28,479 | NEW |
| KORSANA BIOSCIENCES INC | 28,065 | NEW |
| SGMT | 27,246 | NEW |
| ADARX PHARMACEUTICALS INC | 25,136 | NEW |
| ENTXW | 21,397 | NEW |
| ATTOVIA THERAPEUTICS INC | 19,882 | NEW |
| AGEN | 19,715 | NEW |
| RESEARCH ALLIANCE CORP IV | 5,785 | NEW |
| JATT III ACQUISITION CORP | 4,408 | NEW |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|